These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8890852)

  • 1. Vigabatrin overdose.
    Davie MB; Cook MJ; Ng C
    Med J Aust; 1996 Oct; 165(7):403. PubMed ID: 8890852
    [No Abstract]   [Full Text] [Related]  

  • 2. [Subsequent manic disorder due to combination vigabatrin-clomipramine].
    Sastre-Garau P; Thomas P; Beaussart M; Goudemand M
    Encephale; 1994; 20(3):363. PubMed ID: 8088239
    [No Abstract]   [Full Text] [Related]  

  • 3. Aminoaciduria resulting from vigabatrin administration in children with epilepsy.
    Lahat E; Ben-Zeev B; Zlotnik J; Sela BA
    Pediatr Neurol; 1999 Jul; 21(1):460-3. PubMed ID: 10428431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vigabatrin aggravates absences and absence status.
    Panayiotopoulos CP; Agathonikou A; Sharoqi IA; Parker AP
    Neurology; 1997 Nov; 49(5):1467. PubMed ID: 9371946
    [No Abstract]   [Full Text] [Related]  

  • 5. Vigabatrin and complex partial status.
    Arzimanoglou A
    Seizure; 1994 Mar; 3(1):79-80. PubMed ID: 8044458
    [No Abstract]   [Full Text] [Related]  

  • 6. Severe persistent visual field constriction associated with vigabatrin. Chronic refractory epilepsy may have role in causing these unusual lesions.
    Wilson EA; Brodie MJ
    BMJ; 1997 Jun; 314(7095):1693. PubMed ID: 9193311
    [No Abstract]   [Full Text] [Related]  

  • 7. Fatal hepatotoxicity in a child treated with vigabatrin.
    Kellermann K; Soditt V; Rambeck B; Klinge O
    Acta Neurol Scand; 1996 May; 93(5):380-1. PubMed ID: 8800351
    [No Abstract]   [Full Text] [Related]  

  • 8. [Vigabatrin--a new antiepileptic agent].
    Nakken KO; Henriksen O; Johannessen SI
    Tidsskr Nor Laegeforen; 1994 Oct; 114(24):2843-4. PubMed ID: 7998031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Acute psychosis and vigabatrin in childhood].
    Chiaretti A; Castorina M; Tortorolo L; Piastra M; Polidori G
    Pediatr Med Chir; 1994; 16(5):489-90. PubMed ID: 7885961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute pancreatitis associated with dual vigabatrin and lamotrigine therapy.
    Jadresic D
    Seizure; 1994 Dec; 3(4):319. PubMed ID: 7534594
    [No Abstract]   [Full Text] [Related]  

  • 11. Disturbed metabolism of guanidino compounds characterized by elevated excretion of beta-guanidinopropionic acid and gamma-guanidinobutyric acid--an effect of vigabatrin treatment?
    Schulze A; Mayatepek E; Frank S; Marescau B; De Deyn PP; Bachert P
    J Inherit Metab Dis; 1998 Jun; 21(3):268-71. PubMed ID: 9686372
    [No Abstract]   [Full Text] [Related]  

  • 12. [Drug-resistant epilepsy].
    Arroyo S; Rumiá J; Martínez I; Ribalta T
    Rev Neurol; 1998 Nov; 27(159):867-71. PubMed ID: 9859169
    [No Abstract]   [Full Text] [Related]  

  • 13. Vigabatrin and multifocal myoclonus in adults with partial seizures.
    Neufeld MY; Vishnevska S
    Clin Neuropharmacol; 1995 Jun; 18(3):280-3. PubMed ID: 8635188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychotic and severe behavioural reactions with vigabatrin: a review.
    Ferrie CD; Robinson RO; Panayiotopoulos CP
    Acta Neurol Scand; 1996 Jan; 93(1):1-8. PubMed ID: 8825264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe persistent visual field constriction associated with vigabatrin. Asymptomatic as well as symptomatic defects occur with vigabatrin.
    Mackenzie R; Klistorner A
    BMJ; 1998 Jan; 316(7126):233. PubMed ID: 9468717
    [No Abstract]   [Full Text] [Related]  

  • 16. Vigabatrin-induced gingival overgrowth.
    Katz J; Givol N; Chaushu G; Taicher S; Shemer J
    J Clin Periodontol; 1997 Mar; 24(3):180-2. PubMed ID: 9083902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advancements in epilepsy.
    Wyler AR; Vossler DG
    Surg Neurol; 1997 Aug; 48(2):106-9. PubMed ID: 9242233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vigabatrin aggravates absences and absence status.
    Cocito L; Primavera A
    Neurology; 1998 Nov; 51(5):1519-20. PubMed ID: 9818915
    [No Abstract]   [Full Text] [Related]  

  • 19. Severe persistent visual field constriction associated with vigabatrin. Patients taking vigabatrin should have regular visual field testing.
    Blackwell N; Hayllar J; Kelly G
    BMJ; 1997 Jun; 314(7095):1694. PubMed ID: 9193313
    [No Abstract]   [Full Text] [Related]  

  • 20. Obstructive sleep apnoea following rapid weight gain secondary to treatment with vigabatrin (Sabril).
    Lambert MV; Bird JM
    Seizure; 1997 Jun; 6(3):233-5. PubMed ID: 9203253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.